![](/img/cover-not-exists.png)
PCN178 - COST-EFFECTIVENESS OF PEMBROLIZUMAB AS SECOND-LINE TREATMENT FOR PATIENTS WITH ADVANCED UROTHELIAL CANCER IN FRANCE
Robert, J., Culine, S., Roupret, M., Zhong, Y., Prabhu, V.S., Xu, R., Li, H., Lafuma, A., Bensimon, L., Clement, A.Volume:
21
Journal:
Value in Health
DOI:
10.1016/j.jval.2018.09.261
Date:
October, 2018
File:
PDF, 381 KB
2018